Posted inGenetics
Protein Core Stability Rules Open Door for Faster Protein Design
It has long been thought that protein function and stability are highly sensitive to changes in the composition of the…
Posted inBiotechnology
BMS names AstraZeneca’s Cristian Massacesi as new chief medical officer
Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to leave the Anglo-Swedish…
Posted inBiotechnology
‘We will crack gene therapy’: Elevidys fallout doesn’t dent Roche’s hopes for modality
The uncertainty around the future of Elevidys hasn’t destroyed Roche’s belief in the potential of gene therapies, the Swiss company’s…
Posted inBiotechnology
Memo pushes kidney drug to phase 3 despite primary endpoint miss
A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of…
Posted inGenetics
AI-Designed Proteins Enable Scalable Precision Immunotherapy
[Luismmolina/Getty Images] Within each individual’s immune system is a unique repertoire of billions of T cells patrolling the body to…
Posted inGenetics
Representational Drift of Hippocampal Neurons Alters Spatial Memory in Mice
We often think of memory as stable—a mental archive that stores experiences in neat, retrievable files. But what if those…
Posted inGenetics
The Road from HGP to Multiomics with Francis Collins
In the second keynote talk in GEN’s “The State of Multiomics and NGS” virtual summit, originally broadcast on April 23,…
Posted inBiotechnology
Chutes & Ladders—Ikena and Inmagene choose CEO for soon-to-be-combined company
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please…
Posted inBiotechnology
Lilly opens Gate to new small-molecule drug class with $856M biobucks deal
Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to…
Posted inBiotechnology
Brandon Capital raises $290M for its largest life sciences fund yet
Australian life sciences venture capital firm Brandon Capital has closed its largest fund yet, raising A$439 million (about $290 million)…